Wells Fargo Reiterates an 'Outperform' on Vertex (VRTX); Successful Phase III Could Have Multi-Billion Dollar Potential
Tweet Send to a FriendGet Alerts VRTX Hot Sheet
Price: $79.49 --0%
Rating Summary:
17 Buy, 11 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Rating Summary:
17 Buy, 11 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Trade VRTX Now!
Wells Fargo reiterates an 'Outperform' on Vertex (NASDAQ: VRTX) price target range $65-$69.
Analyst, Brian Abrahams, said, "We believe phase II '770/'809 cystic fibrosis (CF) data increase likelihood of phase III success and approvability of combo and risk/reward into Alios nuc data is reasonable."
Abrahams also noted that the data was presented in a somewhat different way vs. prior disclosures and it raised a few questions. However, he feels that overall success in a phase III could have multibillion dollar potential.
For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.
Shares of Vertex closed at $61.11 yesterday, with a 52 week range of $26.50-$66.10.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Brian Abrahams, said, "We believe phase II '770/'809 cystic fibrosis (CF) data increase likelihood of phase III success and approvability of combo and risk/reward into Alios nuc data is reasonable."
Abrahams also noted that the data was presented in a somewhat different way vs. prior disclosures and it raised a few questions. However, he feels that overall success in a phase III could have multibillion dollar potential.
For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.
Shares of Vertex closed at $61.11 yesterday, with a 52 week range of $26.50-$66.10.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- UPDATE: Vanda Pharmaceuticals (VNDA) Opens Higher; Lazard Raises PT to $17
- Supernus (SUPN) PT Trimmed at Jefferies, But Survey Shows Significant Market Opportunity
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Wells Fargo
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
